Vor Biopharma Inc.

Vor Biopharma Inc. (VOR) priced its initial public offering on Feb 8, 2021 at $18.00 per share, raising $176.9M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $641.6M. Goldman Sachs was lead-left underwriter, joined by Evercore ISI, Barclays and Stifel. Cooley advised the company and Latham & Watkins advised the underwriters.

Vor Biopharma Inc. is a cell therapy company developing treatments for hematological malignancies such as acute myeloid leukemia. Its approach engineers patients' stem cells so that targeted therapies can be used with curative intent, addressing relapse after hematopoietic stem cell transplant.

Status

IPO

Ticker

VOR

Exchange

Nasdaq Global Select

Priced

Feb 8, 2021

IPO price

$18.00

Raised

$176.9M

Market cap at IPO price

$641.6M

First filed

Jan 15, 2021

Underwriters

Goldman Sachs, Evercore ISI, Barclays and Stifel

Company counsel

Cooley

Underwriters' counsel

Latham & Watkins

Sector

Biotech & pharma

Country / state

MA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.